Proteome Sciences plc (PMSNF) Stock Price & Analysis
Proteome Sciences plc (PMSNF) — price $0.01 (0.00%), as of the Nov 19, 2026 trading session; market cap $3.51M.
Educational signal · not a buy or sell recommendation · How to read this
Proteome Sciences plc · PMSNF
Proteome Sciences plc offers specialized contract research services focused on protein biomarker identification and validation, serving pharmaceutical, biotechnology, and academic clients globally. The company leverages proprietary analytical solutions and bioinformatics tools to support drug development and personalized medicine initiatives.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.01 | |
| Change on the day | 0.00% | |
| Market capitalisation | $3.51M | — |
| Shares traded on the day | 4.0K |
Price & events
Other perspectives
Council score for Proteome Sciences (PMSNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Proteome Sciences (PMSNF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Proteome Sciences plc (PMSNF) is the company analyzed here. It employs 32 people. In Q2 FY2026 it reported revenue of £2M and net income of -£1M. The market values it at $3.51M.
What do the latest results show for Proteome Sciences (PMSNF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of £2M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | £2M | -£1M | -£0.0041 (diluted) |
| Q4 FY2025 | £2M | -£920,850 | -£0.0031 (diluted) |
| Q2 FY2025 | £2M | -£2M | -£0.01 (diluted) |
| Q4 FY2024 | £3M | -£1M | -£0.0040 (diluted) |
What are the financial strengths and risks for Proteome Sciences (PMSNF)?
Short answer · as of
The distress and quality screens read Altman Z -15.54 · Piotroski F 4. Trailing ratios: ROE 23.8% · ROA -30.2% · current ratio 0.12 · earnings yield -50.1% · free-cash-flow yield 7.8%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PMSNF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PMSNF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About PMSNF
These answers are editorial: 1 of these 8 answers is drawn from the PMSNF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is PMSNF a good stock to buy?
Stock Expert AI does not rate PMSNF buy, sell or hold. Proteome Sciences plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PMSNF stock price today?
The last price recorded for Proteome Sciences plc (PMSNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the primary risks associated with investing in Proteome Sciences plc, particularly given its market listing?
Investing in Proteome Sciences plc carries several notable risks. A primary concern is its financial performance, characterized by ongoing negative profit and gross margins, indicating the company is not currently profitable.
What are the key factors to evaluate for PMSNF?
Evaluate PMSNF on fundamentals, analyst consensus, and risk factors. Therapeutic Area Specialization: Deepening expertise and marketing efforts in specific high-growth therapeutic areas, such as oncology, neurology, or infectious diseases, where biomarker discovery is particularly critical, could enhance Proteome Sciences' market position. Not financial advice.
How frequently does PMSNF data refresh on this page?
PMSNF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PMSNF's recent stock price performance?
Proteome Sciences plc (PMSNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise and proprietary technologies in protein biomarker discovery and validation. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PMSNF overvalued or undervalued right now?
Proteome Sciences plc (PMSNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PMSNF before investing?
Before investing in Proteome Sciences plc (PMSNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 8 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com